The Reason Behind the Increase in Eli Lilly’s Stock
Eli Lilly’s Stock Performance and Recent Developments Shares of Eli Lilly, known for its weight-loss medications Mounjaro and Zepbound, saw a modest increase of 3.6% by 10:30 a.m. ET. This uptick came amidst favorable news for Lilly and some setbacks for its competitor, Novo Nordisk. In the morning, Novo Nordisk, the Danish pharmaceutical firm behind […]
Study suggests Eli Lilly’s weight-loss medication may reduce signals for binge eating.
Researchers studying brain activity in patients with significant overeating issues found that Eli Lilly’s weight loss medicine, GLP-1, seems to temporarily reduce hunger signals in the brain’s “reward center.” This marks the first time direct brain activity measurements have been taken from individuals receiving tirzepatide—marketed as Mounjaro for diabetes and Zepbound for weight loss—which showcased […]
Eli Lilly’s Inluriyo is approved for treating advanced breast cancer
FDA Approves New Treatment for Advanced Breast Cancer The U.S. Food and Drug Administration has green-lighted a new option for treating advanced breast cancer. Eli Lilly announced the approval of Inluriyo, which is an oral estrogen receptor antagonist, on September 25. This drug is aimed at adults suffering from specific types of the disease. These […]
ETFs Under Scrutiny Following Eli Lilly’s Strong Q2 Results and Poor Obesity Data
Eli Lilly Reports Strong Second Quarter Results Eli Lilly and Company has recently announced impressive second-quarter results, largely thanks to significant sales in weight loss and diabetes medications. These results surpassed both revenue and earnings estimates, leading the drugmaker to revise its fiscal year projections upward. Interestingly, despite this robust performance, Eli Lilly’s stocks experienced […]
Eli Lilly’s weight loss medication shows potential, but it’s not as effective as injections.
Eli Lilly’s Weight Loss Pill Trial Results Eli Lilly has revealed that its experimental oral weight loss medication, Orforglipron, helped participants reduce their body weight by roughly 12% on average during late-stage trials, a company update noted on Thursday. However, this outcome appears to fall short compared to similar injectable treatments available in the market. […]